COEP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
COEP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Coeptis Therapeutics Holdings's EBITDA per Share for the three months ended in Dec. 2023 was $-0.10.
During the past 3 years, the average EBITDA Per Share Growth Rate was -22.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 4 years, the highest 3-Year average EBITDA Per Share Growth Rate of Coeptis Therapeutics Holdings was -22.70% per year. The lowest was -22.70% per year. And the median was -22.70% per year.
For the Biotechnology subindustry, Coeptis Therapeutics Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Coeptis Therapeutics Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Coeptis Therapeutics Holdings's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
Coeptis Therapeutics Holdings (NAS:COEP) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Thank you for viewing the detailed overview of Coeptis Therapeutics Holdings's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Tara Desilva | director | 105 BRADFORD RD., SUITE 420, WEXFORD PA 15090 |
David Mehalick | director, 10 percent owner, officer: CEO and President | 5000 TRESSDALE DRIVE, GIBSONIA PA 15044 |
Christopher P. Cochran | director | 105 BRADFORD RD., SUITE 420, WEXFORD PA 15090 |
Gene Salkind | director | 1165 WRACK ROAD, MEADOWBROOK PA 19046 |
Daniel Alexander Yerace | director, officer: VP of Operations | 402 SCHOMBURG COURT, CRANBERRY TOWNSHIP PA 16066 |
Chris Calise | director, 10 percent owner, officer: Chief Financial Officer | 801 S. POINTE DRIVE SUITE TH-1, MIAMI BEACH FL 33139 |
Philippe Deschamps | director | 105 BRADFORD RD, SUITE 420, WEXFORD PA 15090 |
Christine Elise Sheehy | officer: CFO and Secretary | 206 TAMARACK DRIVE, MARS PA 16046 |
Harraden Circle Investments, Llc | 10 percent owner | 299 PARK AVE, 21ST FLOOR, NEW YORK NY 10171 |
Harraden Circle Investors Gp, Lp | 10 percent owner | 299 PARK AVE., 21ST FLOOR, NEW YORK NY 10171 |
Harraden Circle Investors Gp, Llc | 10 percent owner | 299 PARK AVE., 21ST FLOOR, NEW YORK NY 10171 |
Fortmiller Frederick Vincent Jr. | 10 percent owner | 151 LULL ROAD, NEW BOSTON NH 03070 |
Harraden Circle Investors, Lp | 10 percent owner | 299 PARK AVENUE, 21ST FLOOR, NEW YORK NY 10171 |
Plc Barclays | 10 percent owner | 1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP |
Paul J Glazer | 10 percent owner | 250 WEST 55TH ST, SUITE 30A, NEW YORK NY 10019 |
From GuruFocus
By PRNewswire PRNewswire • 03-29-2023
By PRNewswire PRNewswire • 02-07-2023
By PRNewswire PRNewswire • 11-15-2022
By PRNewswire PRNewswire • 06-16-2023
By PRNewswire • 08-17-2023
By PRNewswire PRNewswire • 04-18-2023
By PRNewswire PRNewswire • 11-08-2022
By PRNewswire PRNewswire • 03-21-2023
By PRNewswire • 09-14-2023
By GuruFocus Research GuruFocus Editor • 02-06-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.